News
AAN: Study supports safety of fingolimod for MS
Key clinical point: Results of an ongoing study support the safety of fingolimod for long-term treatment of patients with relapsing-remitting...
News
Peginterferon beta-1a MS data show positive early and long-term results
Key clinical point: Benefits from peginterferon beta-1a, recently approved in the United States, may start early in the course of treatment and...
News
AAN: Cleveland mobile stroke unit reduces time to thrombolysis
Key clinical point: Mobile stroke units could allow more patients to meet a door-to-needle (DTN) time of under 60 minutes.
News
DECIDE: Daclizumab cuts MS relapse rate by 45%
Key clinical point: Daclizumab high-yield process (DAC HYP), a first-in-class IL-2 immunomodulator, could be a new once-monthly treatment option...
